MAPK1 and cancer: The development of RAF/MEK/ERK inhibitors has significantly improved targeted cancer therapy, and it has also accelerated our understanding of molecular mechanisms that tune the output of Ras signaling, which in turn facilitates the development of next-generation inhibitors.